ArticleJournal of translational medicine2023
CD39 and LDHA affects the prognostic role of NLR in metastatic melanoma patients treated with immunotherapy.
Article in Journal of translational medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 27 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
27 citing papers in PubMed, 2 syntheses or guidelines pooled it, 33 citations in OpenAlex.
- Predictive value of serum biomarkers for survival in melanoma: a systematic review and meta-analysis.Scientific reports · 2026Pooled it
- Prognostic value of inflammatory markers NLR, PLR, LMR, dNLR, ANC in melanoma patients treated with immune checkpoint inhibitors: a meta-analysis and systematic review.Frontiers in immunology · 2024Pooled it
- Association between GRIm score and response to nivolumab monotherapy in patients with advanced malignant melanoma.Journal of cancer research and clinical oncology · 2026Article
- Construction and validation of a prognostic model for lung adenocarcinoma based on necrotic cell death triggered by sodium overload-related coexpressed genes.Frontiers in genetics · 2026Article
- Charting the immune terrain: a novel risk model for thyroid cancer prognosis.Frontiers in genetics · 2026Article
- Comprehensive analysis of gene signature linking hypoxia and lactylation for predicting prognosis and immunotherapy response in patients with gastric cancer.Translational cancer research · 2025Article
- Genetic Insight into Expression-Defined Melanoma Subtypes and Network Mechanisms: An in Silico Study.Genes · 2025Article
- Identification of a Treg-related gene signature for predicting prognosis and immunosuppression in skin cutaneous melanoma.Clinical and experimental medicine · 2025Article
- Construction of diagnostic model and subtype analysis of major depressive disorder based on PANoptosis key genes.BMC psychiatry · 2025Article
- A Real-World Evaluation of Clinical Prognostic Scores in Advanced Melanoma Treated with Immune Checkpoint Inhibitors.Journal of clinical medicine · 2025Article
- Gene-expression signature predicts autoimmune toxicity in metastatic melanoma.Journal for immunotherapy of cancer · 2025Article
- Article
- Genetic and transcriptional insights into immune checkpoint blockade response and survival: lessons from melanoma and beyond.Journal of translational medicine · 2025Article
- Current Treatment Paradigms for Advanced Melanoma with Brain Metastases.International journal of molecular sciences · 2025Review
- Metabolomic signatures in liquid biopsy are associated with overall survival in metastatic melanoma patients treated with immune checkpoint inhibitor therapy.Journal of experimental & clinical cancer research : CR · 2025Article
- Society for Immunotherapy of Cancer (SITC) consensus statement on essential biomarkers for immunotherapy clinical protocols.Journal for immunotherapy of cancer · 2025Article
- Prognostic Biomarkers in Evolving Melanoma Immunotherapy.American journal of clinical dermatology · 2025Review
- PILRA serves as a diagnostic and prognostic biomarker and modulates the tumor immune microenvironment and immunotherapy response in breast cancer.Frontiers in immunology · 2025Article
- Transcriptomic signature can distinguish chronic neutrophilic leukemia from ambiguous neutrophilic leukemias.Frontiers in genetics · 2025Article
- Overcoming Resistance Mechanisms to Melanoma Immunotherapy.American journal of clinical dermatology · 2025Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
18 authors at 3 institutions in 2 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundIdentifying response markers is highly needed to guide the treatment strategy in patients with metastatic melanoma.
methodsA retrospective study was carried out in patients with unresectable/metastatic melanoma (stage IIIb-IV), treated with anti-PD-1 in the first line setting, to better explore the role and the timing of neutrophil/lymphocyte ratio (NLR) as potential biomarker of response. The relationship of NLR with inflammation-immune mediators and the underlying negative effect of raising NLR during immunotherapy, have been investigated with transcriptomic gene analysis.
resultsThe results confirmed previous findings that a high baseline NLR is associated with a poorer prognosis and with higher serum level of lactate dehydrogenase (LDH), regardless of the presence of brain metastases. The transcriptomic analysis showed that high baseline NLR is associated with a characteristic gene signature CCNA1, LDHA and IL18R1, which correlates with inflammation and tumorigenesis. Conversely, low baseline NLR is associated with the signature CD3, SH2D1A, ZAP70 and CD45RA, linked to the immune-activation. The genes positively associated with NLR (CD39 (ENTPD1), PTEN, MYD88, MMP9 and LDH) are involved in processes of immunosuppression, inflammation and tumor-promoting activity. Increased expression of CD39 correlated with TGFβ
conclusionsThese results suggest that increasing NLR is associated with an increased neutrophil population, with polarization to the N2 phenotype, and this process may be the basis for the negatively prognostic role of NLR.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.